 |
42 Diseases |  |
12 Trials |
|
12 Trials |  |
1286 News |  |
| «12...3456789101112131415» |
- ||| Vyvanse (lisdexamfetamine) / Shionogi, Takeda
Reimbursement: @CVSHealth is the worst one because our prescription insurance runs through them amd my household's scripts are multiple and some are very expensive (ex: husband's 20 mg dose of adderall XR 2x a day, daughter's Vyvanse). I literally can't boycott them. (Twitter) - May 17, 2019
- | Vyvanse (lisdexamfetamine) / Shionogi, Takeda
Journal: Assessment of lisdexamfetamine dimesylate stability and identification of its degradation product by NMR spectroscopy. (Pubmed Central) - May 13, 2019
LDX solutions subjected to 1M (4 + 12 h) acid and alkaline hydrolysis were evaluated by NMR spectra (1H NMR, 13C NMR, HSQC and HMBC). LDX degradation product (DP) was identified and its structure elucidated as a diastereoisomer of LDX: (2R)-2,6-diamino-N-[(2S)-1-phenylpropan-2-yl] hexanamide without their physical separation.
- | lisdexamfetamine / Generic mfg.
New P3 trial: Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Maintenance Treatment (clinicaltrials.gov) - Apr 23, 2019
P3, N=80, Recruiting, Sponsor: Yale University
- | lisdexamfetamine / Generic mfg.
New P3 trial: Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Acute Treatment (clinicaltrials.gov) - Apr 22, 2019
P3, N=180, Recruiting, Sponsor: Yale University
- | lisdexamfetamine / Generic mfg., Daytrana (methylphenidate transdermal system) / Hisamitsu
Trial completion date, Trial primary completion date: Stimulant Effects on Disruptive Behavior (clinicaltrials.gov) - Apr 12, 2019
P4, N=10, Recruiting, Sponsor: Matthew J O'Brien, PhD, BCBA-D
LDX degradation product (DP) was identified and its structure elucidated as a diastereoisomer of LDX: (2R)-2,6-diamino-N-[(2S)-1-phenylpropan-2-yl] hexanamide without their physical separation. Trial completion date: Jan 2019 --> Jan 2021 | Trial primary completion date: Jan 2019 --> Jan 2021
- | methylphenidate tablet / generics
Journal: Trends in use of prescription stimulants in the United States and Territories, 2006 to 2016. (Pubmed Central) - Apr 9, 2019
There were dynamic changes but also regional disparities in the use of stimulant medications. Future research is needed to better understand the reasons for the sizable regional and ethnic variations in use of these controlled substances.
- | Vyvanse (lisdexamfetamine) / Shionogi, Takeda, Topamax (topiramate) / J&J
Clinical, Review, Journal: Pharmacotherapeutic strategies for treating binge eating disorder. Evidence from clinical trials and implications for clinical practice. (Pubmed Central) - Apr 9, 2019
Consequently, as a general rule, the use of an FDA approved medication should always be preferred. However, when in the presence of concomitant psychiatric conditions such as anxiety or depression, other medications that have proven efficacy in those comorbid conditions can be used and may contextually provide a benefit for BED.
- ||| lisdexamfetamine / Generic mfg.
Enrollment closed, Enrollment change, Trial primary completion date: TBIC: Treatment of Traumatic Brain Injury (TBI)-Related Attention Deficits in Children (clinicaltrials.gov) - Apr 8, 2019
P4, N=20, Active, not recruiting, Sponsor: Vanderbilt University
However, when in the presence of concomitant psychiatric conditions such as anxiety or depression, other medications that have proven efficacy in those comorbid conditions can be used and may contextually provide a benefit for BED. Recruiting --> Active, not recruiting | N=30 --> 20 | Trial primary completion date: Nov 2019 --> Aug 2019
- | Vyvanse (lisdexamfetamine) / Shionogi, Takeda
Why is Vyvanse over $250 a month? (Twitter) - Apr 3, 2019
- ||||| lisdexamfetamine / Generic mfg.
Trial completion, Trial completion date, Trial primary completion date: Safety and Efficacy Study in Preschool Children Aged 4-5 Years With Attention-deficit/Hyperactivity Disorder (ADHD) (clinicaltrials.gov) - Jan 28, 2019
P3, N=199, Completed, Sponsor: Shire
Recruiting --> Active, not recruiting | N=30 --> 20 | Trial primary completion date: Nov 2019 --> Aug 2019 Recruiting --> Completed | Trial completion date: Jun 2019 --> Oct 2018 | Trial primary completion date: Jun 2019 --> Oct 2018
- |||| lisdexamfetamine / Generic mfg.
Enrollment closed, Trial completion date, Trial primary completion date: Safety and Tolerability Study of SPD489 in Preschool Children Aged 4-5 Years, Diagnosed With Attention-deficit/Hyperactivity Disorder (clinicaltrials.gov) - Jan 16, 2019
P3, N=115, Active, not recruiting, Sponsor: Shire
Recruiting --> Completed | Trial completion date: Jun 2019 --> Oct 2018 | Trial primary completion date: Jun 2019 --> Oct 2018 Recruiting --> Active, not recruiting | Trial completion date: May 2019 --> Jan 2020 | Trial primary completion date: May 2019 --> Jan 2020
- | lisdexamfetamine / Generic mfg., Daytrana (methylphenidate transdermal system) / Hisamitsu
Enrollment open, Phase classification, Trial initiation date: Stimulant Effects on Disruptive Behavior (clinicaltrials.gov) - Oct 31, 2018
P4, N=10, Recruiting, Sponsor: Matthew O'Brien
Recruiting --> Active, not recruiting | Trial completion date: May 2019 --> Jan 2020 | Trial primary completion date: May 2019 --> Jan 2020 Not yet recruiting --> Recruiting | Phase classification: PN/A --> P4 | Initiation date: May 2018 --> Oct 2018
- | Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Omega-3 Fatty Acid Supplementation to ADHD Pharmacotherapy in ADHD Adults With Deficient Emotional Self-Regulation Traits (clinicaltrials.gov) - Oct 23, 2018
P2, N=2, Completed, Sponsor: Massachusetts General Hospital
Not yet recruiting --> Recruiting | Phase classification: PN/A --> P4 | Initiation date: May 2018 --> Oct 2018 Active, not recruiting --> Completed | N=30 --> 2 | Trial completion date: Nov 2018 --> Nov 2017 | Trial primary completion date: Nov 2018 --> Nov 2017
- ||| lisdexamfetamine / Generic mfg.
Trial completion: Imaging the Effects of Stimulant Medication on Emotional Lability in Patients With ADHD (clinicaltrials.gov) - Oct 11, 2018
P=N/A, N=117, Completed, Sponsor: New York State Psychiatric Institute
Active, not recruiting --> Completed | N=30 --> 2 | Trial completion date: Nov 2018 --> Nov 2017 | Trial primary completion date: Nov 2018 --> Nov 2017 Recruiting --> Completed
- | NN1213 / Novo Nordisk, Intuniv (guanfacine XR) / Shionogi, Takeda
Enrollment change, Trial completion date, Trial primary completion date: An fMRI Study of Stimulant vs. Non-Stimulant Treatment of ADHD (clinicaltrials.gov) - Oct 11, 2018
P=N/A, N=160, Recruiting, Sponsor: New York State Psychiatric Institute
Recruiting --> Completed N=30 --> 160 | Trial completion date: Jul 2018 --> Jul 2020 | Trial primary completion date: Jul 2018 --> Jul 2020
- lisdexamfetamine / Generic mfg.
Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date: Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism (clinicaltrials.gov) - Sep 27, 2018
P4, N=40, Recruiting, Sponsor: JPM van Stralen Medicine Professional
N=30 --> 160 | Trial completion date: Jul 2018 --> Jul 2020 | Trial primary completion date: Jul 2018 --> Jul 2020 Not yet recruiting --> Recruiting | Trial completion date: Oct 2018 --> Oct 2019 | Initiation date: Nov 2017 --> Sep 2018 | Trial primary completion date: Oct 2018 --> Oct 2019
- | NN1213 / Novo Nordisk
Trial completion, Trial completion date, Trial primary completion date: Treatments for Fathers With ADHD and Their At-Risk Children (Fathers Too) (clinicaltrials.gov) - Sep 12, 2018
P4, N=19, Completed, Sponsor: Seattle Children's Hospital
Not yet recruiting --> Recruiting | Trial completion date: Oct 2018 --> Oct 2019 | Initiation date: Nov 2017 --> Sep 2018 | Trial primary completion date: Oct 2018 --> Oct 2019 Recruiting --> Completed | Trial completion date: Jun 2018 --> Aug 2018 | Trial primary completion date: Dec 2017 --> Aug 2018
- | NN1213 / Novo Nordisk
Trial completion date, Trial primary completion date: Follow up Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD) (clinicaltrials.gov) - Aug 28, 2018
P=N/A, N=326, Active, not recruiting, Sponsor: McGill University Health Center
Recruiting --> Completed | Trial completion date: Jun 2018 --> Aug 2018 | Trial primary completion date: Dec 2017 --> Aug 2018 Trial completion date: Jun 2018 --> Feb 2019 | Trial primary completion date: Jun 2018 --> Feb 2019
- | NN1213 / Novo Nordisk
Trial completion date, Trial primary completion date: Efficacy of Cognitive Behavioral Therapy in Treatment of Adults With Attention Deficit Hyperactivity Disorder (clinicaltrials.gov) - Aug 15, 2018
P=N/A, N=200, Active, not recruiting, Sponsor: Lily Hechtman
Trial completion date: Jun 2018 --> Feb 2019 | Trial primary completion date: Jun 2018 --> Feb 2019 Trial completion date: Oct 2017 --> Oct 2018 | Trial primary completion date: Oct 2017 --> Oct 2018
- | NN1213 / Novo Nordisk, Intuniv (guanfacine XR) / Shionogi, Takeda
Enrollment closed, Trial completion date, Trial primary completion date: The Effectiveness of Aerobic Exercise in the Treatment of Adults With Attention Deficit Hyperactivity Disorder (ADHD) (clinicaltrials.gov) - Aug 15, 2018
P=N/A, N=70, Active, not recruiting, Sponsor: McGill University Health Center
Trial completion date: Oct 2017 --> Oct 2018 | Trial primary completion date: Oct 2017 --> Oct 2018 Recruiting --> Active, not recruiting | Trial completion date: Jun 2018 --> Dec 2018 | Trial primary completion date: Jun 2018 --> Dec 2018
- | lisdexamfetamine / Generic mfg.
Enrollment open: Efficacy of Lisdexamfetamine Dimesylate for Promoting Occupational Success in Young Adults With ADHD (clinicaltrials.gov) - Aug 14, 2018
P4, N=20, Recruiting, Sponsor: Gregory Fabiano
Recruiting --> Active, not recruiting | Trial completion date: Jun 2018 --> Dec 2018 | Trial primary completion date: Jun 2018 --> Dec 2018 Not yet recruiting --> Recruiting
- || lisdexamfetamine / Generic mfg.
Trial completion date, Trial primary completion date: Shire SCT: Lisdexamfetamine Treatment for ADHD and SCT (clinicaltrials.gov) - Jul 24, 2018
P2, N=120, Recruiting, Sponsor: New York University School of Medicine
Not yet recruiting --> Recruiting Trial completion date: Jun 2019 --> Dec 2019 | Trial primary completion date: Jun 2018 --> Dec 2018
- | lisdexamfetamine / Generic mfg.
Enrollment open, Trial initiation date: Lisdexamfetamine for Adults With Bulimia Nervosa (clinicaltrials.gov) - Jun 26, 2018
P2, N=30, Recruiting, Sponsor: Aaron Keshen
Trial completion date: Jun 2019 --> Dec 2019 | Trial primary completion date: Jun 2018 --> Dec 2018 Not yet recruiting --> Recruiting | Initiation date: Mar 2018 --> Jun 2018
- ||| lisdexamfetamine / Generic mfg.
Trial completion date, Trial primary completion date: Safety and Tolerability Study of SPD489 in Preschool Children Aged 4-5 Years, Diagnosed With Attention-deficit/Hyperactivity Disorder (clinicaltrials.gov) - Jun 1, 2018
P3, N=100, Recruiting, Sponsor: Shire
Not yet recruiting --> Recruiting | Initiation date: Mar 2018 --> Jun 2018 Trial completion date: Jan 2021 --> May 2019 | Trial primary completion date: Jan 2021 --> May 2019
- | lisdexamfetamine / Generic mfg.
Enrollment change: Effectiveness and Duration of Effect of Open Treatment in Attention Deficit Hyperactivity Disorder (ADHD) Patients Treated With Lisdexamfetamine Dimesylate(Vyvanse) (clinicaltrials.gov) - Apr 3, 2018
P4, N=40, Completed, Sponsor: New York University School of Medicine
Trial completion date: Jan 2021 --> May 2019 | Trial primary completion date: Jan 2021 --> May 2019 N=20 --> 40
- || lisdexamfetamine / Generic mfg.
Trial completion date, Trial primary completion date: Imaging the Effects of Stimulant Medication on Emotional Lability in Patients With ADHD (clinicaltrials.gov) - Apr 2, 2018
P=N/A, N=100, Recruiting, Sponsor: New York State Psychiatric Institute
N=20 --> 40 Trial completion date: Feb 2018 --> Jun 2018 | Trial primary completion date: Feb 2018 --> Jun 2018
- lisdexamfetamine / Generic mfg.
Trial completion date, Trial primary completion date: TBIC: Treatment of Traumatic Brain Injury (TBI)-Related Attention Deficits in Children (clinicaltrials.gov) - Feb 28, 2018
P4, N=30, Recruiting, Sponsor: Vanderbilt University
Trial completion date: Feb 2018 --> Jun 2018 | Trial primary completion date: Feb 2018 --> Jun 2018 Trial primary completion date: Nov 2018 --> Nov 2019 | Trial completion date: Nov 2018 --> Nov 2019
- | lisdexamfetamine / Generic mfg., Daytrana (methylphenidate transdermal system) / Hisamitsu
New trial: Stimulant Effects on Disruptive Behavior (clinicaltrials.gov) - Feb 5, 2018
P=N/A, N=10, Not yet recruiting, Sponsor: Matthew O'Brien
- | lisdexamfetamine / Generic mfg.
New P2 trial: Lisdexamfetamine for Adults With Bulimia Nervosa (clinicaltrials.gov) - Jan 12, 2018
P2, N=30, Not yet recruiting, Sponsor: Aaron Keshen
- | lisdexamfetamine / Generic mfg.
New P4 trial: Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism (clinicaltrials.gov) - Nov 9, 2017
P4, N=40, Not yet recruiting, Sponsor: JPM van Stralen Medicine Professional
- lisdexamfetamine / Generic mfg.
New trial: AGUALIS: Experimental fMRI Study of Guanfacine and Lisdexamfetamine in ADHD Adolescents (clinicaltrials.gov) - Nov 7, 2017
P=N/A, N=20, Not yet recruiting, Sponsor: King's College London
- | lisdexamfetamine / Generic mfg.
Enrollment closed, Trial primary completion date: Follow up Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD) (clinicaltrials.gov) - Sep 20, 2017
P=N/A, N=326, Active, not recruiting, Sponsor: McGill University Health Center
Trial primary completion date: Nov 2018 --> Nov 2019 | Trial completion date: Nov 2018 --> Nov 2019 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2017 --> Jun 2018
- | lisdexamfetamine / Generic mfg., Intuniv (guanfacine XR) / Shionogi, Takeda
Trial primary completion date: An fMRI Study of Stimulant vs. Non-Stimulant Treatment of ADHD (clinicaltrials.gov) - Sep 15, 2017
P=N/A, N=30, Recruiting, Sponsor: New York State Psychiatric Institute
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2017 --> Jun 2018 Trial primary completion date: Jul 2017 --> Jul 2018
- |||||| lisdexamfetamine / Generic mfg.
Enrollment open: Safety and Efficacy Study in Preschool Children Aged 4-5 Years With Attention-deficit/Hyperactivity Disorder (ADHD) (clinicaltrials.gov) - Sep 10, 2017
P3, N=195, Recruiting, Sponsor: Shire
Trial primary completion date: Jul 2017 --> Jul 2018 Not yet recruiting --> Recruiting
- | lisdexamfetamine / Generic mfg.
Trial primary completion date: Efficacy of Cognitive Behavioral Therapy in Treatment of Adults With Attention Deficit Hyperactivity Disorder (clinicaltrials.gov) - Aug 30, 2017
P=N/A, N=200, Active, not recruiting, Sponsor: Lily Hechtman
Not yet recruiting --> Recruiting Trial primary completion date: Jun 2017 --> Oct 2017
- | lisdexamfetamine / Generic mfg.
Enrollment change, MRI: LDX and Functional Magnetic Resonance Imaging (fMRI in Menopausal Women (clinicaltrials.gov) - Aug 30, 2017
P4, N=18, Completed, Sponsor: University of Pennsylvania
Trial primary completion date: Jun 2017 --> Oct 2017 N=14 --> 18
- | lisdexamfetamine / Generic mfg., Intuniv (guanfacine XR) / Shionogi, Takeda
Trial primary completion date: The Effectiveness of Aerobic Exercise in the Treatment of Adults With Attention Deficit Hyperactivity Disorder (ADHD) (clinicaltrials.gov) - Aug 30, 2017
P=N/A, N=70, Recruiting, Sponsor: McGill University Health Center
N=14 --> 18 Trial primary completion date: Jun 2017 --> Jun 2018
- | lisdexamfetamine / Generic mfg.
Trial primary completion date: Omega-3 Fatty Acid Supplementation to ADHD Pharmacotherapy in ADHD Adults With Deficient Emotional Self-Regulation Traits (clinicaltrials.gov) - Aug 24, 2017
P2, N=30, Active, not recruiting, Sponsor: Massachusetts General Hospital
Trial primary completion date: Jun 2017 --> Jun 2018 Trial primary completion date: Nov 2017 --> Nov 2018
- |||||||||| lisdexamfetamine / Generic mfg.
New P3 trial: Safety and Efficacy Study in Preschool Children Aged 4-5 Years With Attention-deficit/Hyperactivity Disorder (ADHD) (clinicaltrials.gov) - Aug 23, 2017
P3, N=195, Not yet recruiting, Sponsor: Shire
- | lisdexamfetamine / Generic mfg.
Trial completion, Trial primary completion date: Clinical Efficacy of Lisdexamfetamine for Methamphetamine Dependence (clinicaltrials.gov) - Aug 22, 2017
P1, N=19, Completed, Sponsor: University of Arkansas
Trial primary completion date: Nov 2017 --> Nov 2018 Active, not recruiting --> Completed | Trial primary completion date: Jul 2017 --> May 2016
- | lisdexamfetamine / Generic mfg.
Enrollment open: IMPRES: IMProving Executive Function Study (clinicaltrials.gov) - Aug 17, 2017
P4, N=100, Recruiting, Sponsor: University of Pennsylvania
Active, not recruiting --> Completed | Trial primary completion date: Jul 2017 --> May 2016 Not yet recruiting --> Recruiting
- | lisdexamfetamine / Generic mfg.
Trial completion: Lisdexamfetamine Dimesylate in the Treatment of Adult ADHD With Anxiety Disorder Comorbidity (clinicaltrials.gov) - Aug 2, 2017
P4, N=42, Completed, Sponsor: Centre for Anxiety, Attention Deficit and Trauma, Ontario, Canada
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- || lisdexamfetamine / Generic mfg.
Trial primary completion date: Imaging the Effects of Stimulant Medication on Emotional Lability in Patients With ADHD (clinicaltrials.gov) - Jun 27, 2017
P=N/A, N=100, Recruiting, Sponsor: New York State Psychiatric Institute
Active, not recruiting --> Completed Trial primary completion date: Mar 2017 --> Feb 2018
- | lisdexamfetamine / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: LEIA: Lisdexamfetamine's Effect In ADHD in the Brain and Cognition (clinicaltrials.gov) - Jun 22, 2017
P4, N=13, Completed, Sponsor: University of California, Davis
Trial primary completion date: Mar 2017 --> Feb 2018 Recruiting --> Completed | N=40 --> 13 | Trial primary completion date: Aug 2015 --> May 2017
- | lisdexamfetamine / Generic mfg.
New P4 trial: IMPRES: IMProving Executive Function Study (clinicaltrials.gov) - Jun 14, 2017
P4, N=100, Not yet recruiting, Sponsor: University of Pennsylvania
- | lisdexamfetamine / Generic mfg.
Enrollment open, Surgery, Bariatric surgery: Pharmacokinetics of Lisdexamfetamine (Vyvanse (clinicaltrials.gov) - May 16, 2017
P4, N=20, Recruiting, Sponsor: North Dakota State University
Recruiting --> Completed | N=40 --> 13 | Trial primary completion date: Aug 2015 --> May 2017 Not yet recruiting --> Recruiting
- | lisdexamfetamine / Generic mfg.
Enrollment change, Trial withdrawal, Trial primary completion date: E2LDX: E2 and LDX for the Treatment of Cognitive Complaints After Oophorectomy (clinicaltrials.gov) - Mar 24, 2017
P=N/A, N=0, Withdrawn, Sponsor: University of Pennsylvania
Not yet recruiting --> Recruiting N=30 --> 0 | Active, not recruiting --> Withdrawn | Trial primary completion date: Jun 2020 --> Jul 2013
- | lisdexamfetamine / Generic mfg.
Trial primary completion date: Efficacy of Cognitive Behavioral Therapy in Treatment of Adults With Attention Deficit Hyperactivity Disorder (clinicaltrials.gov) - Mar 22, 2017
P=N/A, N=200, Active, not recruiting, Sponsor: Lily Hechtman
N=30 --> 0 | Active, not recruiting --> Withdrawn | Trial primary completion date: Jun 2020 --> Jul 2013 Trial primary completion date: Dec 2016 --> Jun 2017
- | Intuniv (guanfacine XR) / Shionogi, Takeda
Trial primary completion date: ADAPT: ADHD Medication and Predictors of Treatment Outcome (clinicaltrials.gov) - Mar 22, 2017
P=N/A, N=2000, Enrolling by invitation, Sponsor: Karolinska Institutet
Trial primary completion date: Dec 2016 --> Jun 2017 Trial primary completion date: Mar 2018 --> Mar 2019
- | lisdexamfetamine / Generic mfg.
New P4 trial, Surgery, Bariatric surgery: Pharmacokinetics of Lisdexamfetamine (Vyvanse (clinicaltrials.gov) - Mar 3, 2017
P4, N=20, Not yet recruiting, Sponsor: North Dakota State University